NL-OMON27857已完成不适用
Safety, toxicity and immunogenicity of HPV16 E7 DNA vaccination in HPV16+ vulvar intraepithelial neoplasia grade III: a phase I study.
KI-AV0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •* Age above 18 years
- •* Willing and able to undergo the planned study procedures
排除标准
- •* Prior treatment with anti-HPV agents
- •* Participation in a study with another investigational drug within 30 days prior to the enrolment in this study
研究者
相似试验
已完成
不适用
Safety, toxicity and immunogenicity of HPV16 E7 DNA vaccination in HPV16+ vulvar intraepithelial neoplasia grade III: a phase I study.VINIIIvulvar dysplasia10038595NL-OMON40423Antoni van Leeuwenhoek Ziekenhuis12
撤回
不适用
Safety, efficacy and immunogenicity of HPV 16 E7 DNA vaccination in HPV related squamous cell cancer.cervical cancersquamous cell cancer10038588NL-OMON38905Antoni van Leeuwenhoek Ziekenhuis35
已完成
不适用
Pharmacokinetic analysis of HPV16 synthetic long peptide vaccination in healthy volunteers using optical imagingHPV16 associated cancerHPV / cancerhuman papillomavirusmalignant tumors10027655NL-OMON42729Centre for Human Drug Research6
已完成
不适用
Vaccin tracking in healthy volunteersHuman Papilloma Virus 16 Peptide vaccinFluorescencePharmacokineticsNL-OMON23478Centre for Human Drug Research (CHDR)Leiden University Medical Center (LUMC)6
招募中
不适用
NWRD09 for HPV-16 Positive and HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer Patients.Cervical CancerIntraepithelial NeoplasiaNCT06741150Newish Technology (Beijing) Co., Ltd.18